Skip to main content
Top
Published in: Rheumatology International 8/2015

01-08-2015 | Original Article - Observational Research

Risk factors for subclinical inflammation in children with Familial Mediterranean fever

Authors: Meral Torun Bayram, Tufan Çankaya, Elçin Bora, Salih Kavukçu, Ayfer Ülgenalp, Alper Soylu, Mehmet Türkmen

Published in: Rheumatology International | Issue 8/2015

Login to get access

Abstract

Familial Mediterranean fever (FMF) is the most common autosomal recessive inherited inflammatory disease characterized by attacks of painful inflammation. Some patients with FMF have subclinical inflammation persisting between the attacks. We aimed to identify the demographic, clinical and genetic risk factors for subclinical inflammation in children with FMF. The medical records of the children with FMF were evaluated retrospectively for acute-phase response along with gender, age at the onset of symptoms and at the time of diagnosis, clinical signs and symptoms, the presence of amyloidosis and MEFV genotype. Patients with persistently elevated acute-phase response between the attacks were considered to have subclinical inflammation. Patients with or without subclinical inflammation (Group 1 and Group 2, respectively) were compared for the parameters defined above. Independent risk factors for subclinical inflammation were identified by multivariate logistic regression analysis. There were 105 children (male/female: 52/53) who were compliant on colchicine treatment. Subclinical inflammation was detected in 22 (20 %) patients. Group 1 had significantly higher rate of myalgia, arthritis/arthralgia, erysipelas like erythema, amyloidosis, protracted febrile myalgia and M694V mutation compared with Group 2. However, only the presence of myalgia and erysipelas like erythema were found to be independent risk factors for subclinical inflammation (OR 9.8 and 5.9, respectively). Children with FMF who have myalgia and erysipelas like erythema during the attacks are particularly at risk of ongoing inflammation and should be closely monitored for subclinical inflammation even during attack-free periods.
Literature
1.
go back to reference Ozturk C, Halıcıoğlu O, Coker I, Gulez N, Sutçuoğlu S, Karaca N, Aksu G, Kutukcular N (2012) Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol 31:493–501PubMedCrossRef Ozturk C, Halıcıoğlu O, Coker I, Gulez N, Sutçuoğlu S, Karaca N, Aksu G, Kutukcular N (2012) Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clin Rheumatol 31:493–501PubMedCrossRef
2.
go back to reference Ozçakar ZB, Yalçinkaya F, Yüksel S, Acar B, Gökmen D, Ekim M (2006) Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 25(2):149–152PubMedCrossRef Ozçakar ZB, Yalçinkaya F, Yüksel S, Acar B, Gökmen D, Ekim M (2006) Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol 25(2):149–152PubMedCrossRef
3.
go back to reference The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807CrossRef The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807CrossRef
4.
go back to reference Padeh S, Berkun Y (2007) Auto-inflammatory fever syndromes. Rheum Dis Clin N Am 33:585–623CrossRef Padeh S, Berkun Y (2007) Auto-inflammatory fever syndromes. Rheum Dis Clin N Am 33:585–623CrossRef
5.
go back to reference Saatçi U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, Arslan S (1997) Familial Mediterranean Fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:619–623PubMedCrossRef Saatçi U, Ozen S, Ozdemir S, Bakkaloglu A, Besbas N, Topaloglu R, Arslan S (1997) Familial Mediterranean Fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 156:619–623PubMedCrossRef
7.
go back to reference Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415PubMedCrossRef Tunca M, Kirkali G, Soytürk M, Akar S, Pepys MB, Hawkins PN (1999) Acute phase response and evolution of familial Mediterranean fever. Lancet 353(9162):1415PubMedCrossRef
9.
go back to reference Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1876–1885CrossRef Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, Migdal A, Padeh S, Pras M (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1876–1885CrossRef
10.
go back to reference Majeed HA, Al-Qudah AK, Qubain H, Shahin HM (2000) The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 30(2):138–143PubMedCrossRef Majeed HA, Al-Qudah AK, Qubain H, Shahin HM (2000) The clinical patterns of myalgia in children with familial Mediterranean fever. Semin Arthritis Rheum 30(2):138–143PubMedCrossRef
11.
go back to reference Tchernitchko D, Legendre M, Delahaye A, Cazeneuve C, Niel F, Goossens M, Amselem S, Girodon E (2003) Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. Clin Chem 49:1942–1945PubMedCrossRef Tchernitchko D, Legendre M, Delahaye A, Cazeneuve C, Niel F, Goossens M, Amselem S, Girodon E (2003) Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. Clin Chem 49:1942–1945PubMedCrossRef
12.
go back to reference Çakmak E, Ece A, Kelekçi S, Yolbaş İ, Güneş A, Şen V (2013) Comparison of acute phase response during attack and attack-free period in children with Familial Mediterranean Fever. J Clin Exp Invest 4:213–218CrossRef Çakmak E, Ece A, Kelekçi S, Yolbaş İ, Güneş A, Şen V (2013) Comparison of acute phase response during attack and attack-free period in children with Familial Mediterranean Fever. J Clin Exp Invest 4:213–218CrossRef
13.
go back to reference Lachmann HJ, Sengül B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M, Hawkins PN (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746–750CrossRef Lachmann HJ, Sengül B, Yavuzsen TU, Booth DR, Booth SE, Bybee A, Gallimore JR, Soytürk M, Akar S, Tunca M, Hawkins PN (2006) Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45(6):746–750CrossRef
14.
go back to reference Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, Bassoy Y, Yilmaz E (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509–514PubMed Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F, Bassoy Y, Yilmaz E (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509–514PubMed
15.
go back to reference Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105–112PubMedCrossRef Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7(2):105–112PubMedCrossRef
16.
go back to reference Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A (2005) Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 35(1):57–64PubMedCrossRef Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, Rabinovitz E, Livneh A (2005) Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 35(1):57–64PubMedCrossRef
17.
go back to reference Gershoni-Baruch R, Brik R, Lidar M, Shinawi M, Livneh A (2003) Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 30(2):308–312PubMed Gershoni-Baruch R, Brik R, Lidar M, Shinawi M, Livneh A (2003) Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation. J Rheumatol 30(2):308–312PubMed
18.
go back to reference Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149–1155PubMedCrossRef Gershoni-Baruch R, Brik R, Zacks N, Shinawi M, Lidar M, Livneh A (2003) The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 48(4):1149–1155PubMedCrossRef
19.
go back to reference Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, Shainberg B, Livneh A (2007) A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 37(3):182–188PubMedCrossRef Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, Shainberg B, Livneh A (2007) A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 37(3):182–188PubMedCrossRef
20.
go back to reference Sarı I, Birlik M, Kaşifoğlu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheum 1:21–33CrossRef Sarı I, Birlik M, Kaşifoğlu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheum 1:21–33CrossRef
21.
go back to reference Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 291(18):934–937PubMedCrossRef Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 291(18):934–937PubMedCrossRef
22.
go back to reference Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005PubMedCrossRef Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005PubMedCrossRef
23.
go back to reference Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, Pras M (1996) The changing face of familial Mediterranean fever. Semin Arthritis Rheum 26(3):612–627PubMedCrossRef Livneh A, Langevitz P, Zemer D, Padeh S, Migdal A, Sohar E, Pras M (1996) The changing face of familial Mediterranean fever. Semin Arthritis Rheum 26(3):612–627PubMedCrossRef
24.
go back to reference Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S, Pras M, Livneh A (2001) Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 102(3):272–276PubMedCrossRef Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S, Pras M, Livneh A (2001) Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 102(3):272–276PubMedCrossRef
25.
go back to reference Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977PubMedCrossRef Zemer D, Livneh A, Danon YL, Pras M, Sohar E (1991) Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 34:973–977PubMedCrossRef
26.
go back to reference Zemer D, Pras M, Sohar E, Gafni J (1976) Letter: Colchicine in familial Mediterranean fever. N Engl J Med 294(3):170–171PubMedCrossRef Zemer D, Pras M, Sohar E, Gafni J (1976) Letter: Colchicine in familial Mediterranean fever. N Engl J Med 294(3):170–171PubMedCrossRef
Metadata
Title
Risk factors for subclinical inflammation in children with Familial Mediterranean fever
Authors
Meral Torun Bayram
Tufan Çankaya
Elçin Bora
Salih Kavukçu
Ayfer Ülgenalp
Alper Soylu
Mehmet Türkmen
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 8/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3227-z

Other articles of this Issue 8/2015

Rheumatology International 8/2015 Go to the issue

Letter to the Editor - Food for Thought

Meat consumption and gout: Friend, foe or neither?

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.